Contact us

VETMEDIN^® (pimobendan) Chewable Tablets and VETMEDIN^® Solution (pimobendan oral solution) are for use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN^® should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. 
For more information, please see full prescribing information for Solution or full prescribing information for Chewable Tablets.

VETMEDIN^®-CA1 (pimobendan) are for use only in dogs with preclinical MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly (Stage B2 MMVD, 2019 ACVIM Consensus Statement1). VETMEDIN^®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556. A diagnosis of MMVD should be made by means of a comprehensive physical and cardiac examination, which should include radiography and echocardiography. The most common side effects seen in dogs with Stage B2 MMVD while taking VETMEDIN^®-CA1 Chewable Tablets are cough, vomiting, diarrhea, lethargy and localized pain (such as in the neck or legs). Adverse reactions not related to disease progression in dogs receiving VETMEDIN^®-CA1 included diarrhea, vomiting, pain, lameness, arthritis, urinary tract infection, and seizure.

For more information, please refer to the package insert.